Patch test could help primary care doctors spot melanoma earlier

A new study suggests a painless skin patch test may help family doctors and other frontline providers rule out melanoma sooner, especially in places where dermatology access is limited. Researchers say the approach could reduce unnecessary biopsies and speed referrals, but larger primary care studies are still needed.

Why it matters: - Melanoma accounts for about 1% of skin cancers but causes most skin cancer deaths. - Many patients with suspicious moles or spots first see a primary care doctor, not a dermatologist. - Limited skin-cancer training in primary care can delay diagnosis. - Rural and underserved patients may wait weeks or months for a dermatology visit. - Earlier detection can improve outcomes and make treatment less difficult.

What happened: - Researchers published a review in SKIN: The Journal of Cutaneous Medicine® on a skin patch test called the Pigmented Lesion Assay, or PLA. - The test places a small patch on a suspicious mole or spot and painlessly collects surface skin cells. - A lab then checks the sample for two genes linked to melanoma. - If neither gene is active, the spot has a greater than 99% chance of not being melanoma. - The review focused on whether the test could help primary care doctors identify melanoma earlier.

The details: - In dermatology offices, the patch test has reduced unnecessary biopsies in published studies. - Traditional practice can require 20 to 25 biopsies to find one melanoma. - With the patch test, some studies cut that number to about three biopsies per melanoma. - Follow-up data showed spots with negative patch results remained non-cancerous for at least a year. - The test works across all skin tones. - That matters because melanoma in people with darker skin is often diagnosed later. - The review cites the test as a potential alternative to immediate surgical biopsy in selected cases. - More information is available from the journal's website.

Between the lines: - The biggest promise is not just better testing, but broader access to early skin-cancer screening in clinics that do not have dermatology expertise on hand. - The evidence base looks strongest in dermatology settings, so primary care adoption will depend on whether those results hold in everyday front-line practice. - Insurance coverage remains uneven, which could slow use even if the test performs well. - Training will also matter, because clinicians still need to choose the right lesions for testing.

What's next: - The authors call for larger studies in primary care settings. - Those studies need to test real-world performance outside dermatology offices. - Researchers also want to measure cost-effectiveness. - Wider adoption will likely depend on clearer reimbursement and clinician training.

The bottom line: - The PLA could become a practical tool for primary care doctors trying to catch melanoma sooner, but the strongest case for routine use still needs confirmation outside specialty clinics.